Crr. Hayter et al., A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer, RADIOTH ONC, 56(3), 2000, pp. 329-333
Citations number
18
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Purpose: Between 1994 and 1997, 22 patients with dysphagia from advanced in
curable esophageal cancer were enrolled in a phase I/II prospective study t
o assess the palliative benefit and toxicity of a short course of radiother
apy with chemotherapy.
Methods: The study population included 17 men and five women with a median
age of 69 (range 43-84). Patients were treated with 30 Gy in ten fractions
to the mediastinum with a concurrent single course of chemotherapy (5-FU, 1
000 mg/m(2), days 1-4 and mitomycin-C 10 mg/ m(2), day 1), Swallowing abili
ty was recorded each day on a self-administered diary card using the five p
oint dysphagia index of the MRC (UK), The median baseline MRC swallowing sc
ore was 4 (cannot swallow solids).
Results: Treatment was generally well tolerated, but seven (32%) patients h
ad transient worsening of dysphagia scores immediately following treatment
because of esophagitis; fifteen (68%) achieved a complete response (score 1
: no difficulty on swallowing! with a median time to normalization of swall
owing of 5 weeks. For these patients, the median dysphagia-free interval fr
om time of onset of improvement was 11 weeks (ranee 1-131 weeks) and 11 (73
%) remained dysphagia-free until death.. The remaining patients had no or m
arginal improvement. Univariate analysis showed no difference between respo
nders and non-responders with respect to age, gender, or histology. Median
survival for the entire study population was 20 weeks (range 3-135 weeks).
Conclusions: This prospective trial shows that a short course of radiothera
py plus chemotherapy may produce complete relief of swallowing difficulties
in a substantial proportion of patients with acceptable toxicity. (C) 2000
Elsevier Science Ireland Ltd. All rights reserved.